Contact Congress about S. 1637: MVP Act

Medicaid and Medicare could use clearer rules for drug deals tied to patient results. The bill explains how prices, refunds, and rebates count in those deals.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

MVP Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.

Latest action on S. 1637: Read twice and referred to the Committee on Finance.

Who this affects: This bill mainly affects state Medicaid programs, drug companies, Medicare Part B, and patients who may need expensive or specialized drugs. States could get clearer rules for paying based on whether a drug works. Drug makers would get clearer price-reporting rules and legal protection for some outcome-based payments. Patients could be affected if these deals change which drugs states cover, how quickly they cover them, or how public programs manage costs.

Why this matters: Expensive drugs can be risky for public programs when the benefits are uncertain. This bill tries to let states pay more clearly based on whether a drug works for patients. That could help Medicaid manage costly treatments, but the real effect is not certain. The required federal study is meant to show whether these deals improve access, health results, and costs, or whether Congress needs to change the rules later.

Key provisions in S. 1637

• Drug makers could report more than one Medicaid “best price” for a single drug. This applies when the drug is sold through a value-based purchasing deal and the same type of deal is offered to every state.
• Drug makers could still count a value-based purchasing deal as a bundled sale. That keeps an existing Medicaid pricing option available.
• Medicaid would count some outcome-based payments as price discounts. This includes refunds, rebates, reimbursements, free goods, and lower payments when patients do not meet the deal’s health goals.
• Installment deals would be treated as if the full drug price was paid up front. Medicaid would use that rule for rebate and pricing calculations.
• The Social Security Act would point to the current federal definition of “value-based purchasing arrangement.” That definition is now in 42 C.F.R. section 447.502, a federal Medicaid regulation.

How Modern Action helps you take action on S. 1637

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1637

What is S. 1637?

Medicaid and Medicare could use clearer rules for drug deals tied to patient results. The bill explains how prices, refunds, and rebates count in those deals.

How do I support or oppose S. 1637?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1637?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 1637 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.